Low-dose aspirin in high-risk individuals with screen-detected subsolid lung nodules: A randomized phase II trial

Bernardo Bonanni, Davide Serrano, Patrick Maisonneuve, Giulia Veronesi, Harriet Johansson, Valentina Aristarco, Clara Varricchio, Massimiliano Cazzaniga, Matteo Lazzeroni, Cristiano Rampinelli, Massimo Bellomi, Manuela Vecchi, Lorenzo Spaggiari, Lana Vornik, Powel H. Brown, Therese Beavers, Aliana Guerrieri-Gonzaga, Eva Szabo

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Lung cancer screening by helical low-dose computed tomography detects nonsolid nodules that may be lung adenocarcinoma precursors. Aspirin's anti-inflammatory properties make it an attractive target for prevention of multiple cancers, including lung cancer. Therefore, we conducted a phase IIb trial (NCT02169271) to study the efficacy of low-dose aspirin to reduce the size of subsolid lung nodules (SSNs). A total of 98 current or former smokers (67.3% current) undergoing annual lowdose computed tomography screening with persistent SSNs were randomly assigned to receive aspirin 100 mg/day or placebo for 1 year. There was no difference in change in the sum of the longest diameters of target nodules in the placebo and aspirin arm after 12months of treatment (-0.12mm[SD = 1.55 mm] and +0.30mm[SD= 2.54 mm], respectively; 2-sided P=.33 primary endpoint). There were no changes observed in subgroup analyses by individual characteristics or nodule type. One year of low-dose aspirin did not show any effect on lung SSNs. SSNs regression may not be the proper target for aspirin, and/or longer duration may be needed to see SSNs modifications.

Original languageEnglish (US)
Article numberpkaa096
JournalJNCI Cancer Spectrum
Volume4
Issue number6
DOIs
StatePublished - 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Low-dose aspirin in high-risk individuals with screen-detected subsolid lung nodules: A randomized phase II trial'. Together they form a unique fingerprint.

Cite this